Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Lava Therapeutics N.V. (LVTX)

Lava Therapeutics N.V. (LVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments FinancialNewsMedia - Tue Mar 5, 7:30AM CST

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:OCEA),(NASDAQ:LVTX),(NYSE:MRK),(NYSE:ABBV) EQNX::TICKER_END

OCEA : 1.5350 (-11.78%)
ONCY : 1.1700 (-5.65%)
ONC.TO : 1.59 (-5.92%)
LVTX : 3.09 (-0.64%)
MRK : 130.06 (-0.13%)
ABBV : 160.75 (+0.22%)
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments GlobeNewswire - Tue Mar 5, 7:30AM CST

ONCY : 1.1700 (-5.65%)
ONC.TO : 1.59 (-5.92%)
LVTX : 3.09 (-0.64%)
MRK : 130.06 (-0.13%)
ABBV : 160.75 (+0.22%)
Geron (GERN) Reports Q1 Loss, Misses Revenue Estimates Zacks - Thu May 11, 2023

Geron (GERN) delivered earnings and revenue surprises of 22.22% and 85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

GERN : 3.80 (-2.06%)
LVTX : 3.09 (-0.64%)
Selecta Biosciences, Inc. (SELB) Reports Q1 Loss, Misses Revenue Estimates Zacks - Thu May 4, 2023

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -37.50% and 59.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

SELB : 0.8812 (-8.00%)
LVTX : 3.09 (-0.64%)
ITeos Therapeutics, Inc. (ITOS) Q4 Earnings and Revenues Surpass Estimates Zacks - Wed Mar 15, 2023

iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 35.71% and 30.97%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

ITOS : 17.44 (+43.07%)
LVTX : 3.09 (-0.64%)
Curis (CRIS) Reports Q4 Loss, Misses Revenue Estimates Zacks - Mon Mar 13, 2023

Curis (CRIS) delivered earnings and revenue surprises of 14.29% and 4.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

CRIS : 15.72 (-4.78%)
LVTX : 3.09 (-0.64%)
Can LAVA Therapeutics N.V. (LVTX) Climb 198% to Reach the Level Wall Street Analysts Expect? Zacks - Fri Nov 25, 2022

The mean of analysts' price targets for LAVA Therapeutics N.V. (LVTX) points to a 197.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

LVTX : 3.09 (-0.64%)
LAVA Therapeutics N.V. (LVTX) Q3 Earnings Surpass Estimates Zacks - Wed Nov 16, 2022

LAVA Therapeutics N.V. (LVTX) delivered earnings and revenue surprises of 157.14% and 38.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

LVTX : 3.09 (-0.64%)
CDMO : 8.67 (+6.51%)
Will LAVA Therapeutics N.V. (LVTX) Report Negative Q3 Earnings? What You Should Know Zacks - Mon Nov 14, 2022

LAVA Therapeutics N.V. (LVTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LVTX : 3.09 (-0.64%)
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates Zacks - Mon Nov 14, 2022

Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of 1.15% and 131.59%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

VRDN : 13.90 (-0.07%)
LVTX : 3.09 (-0.64%)

Barchart Exclusives

Option Volatility And Earnings Report For May 13- 17 Barchart - 27 minutes ago
Earnings season is slowing down, but we still have a few big names reporting. This week, we have Alibaba, Home Depot, Walmart, Cisco and Deere & Company all reporting. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot